Navigation Links
Allergic-like reactions to iodinated contrast material treated safely with commonly used medications
Date:8/1/2008

Patients who have had acute allergic-like reactions to nonionic iodinated contrast material rarely develop any serious long-term problems and can be treated safely with commonly used medications according to a recent study conducted by researchers at the University of Michigan Hospitals in Ann Arbor.

"While adverse reactions to iodinated contrast media are rare, they are encountered regularly by all physicians who administer contrast material to patients and some of these reactions will require treatment," said Richard Cohan, MD, lead author of the study. "We reviewed our experience to determine how often we encountered these reactions in our practice and how often the reactions required treatment. We also wanted to know what happened to those patients who required treatment, particularly when they had reactions that were moderate or severe," said Dr. Cohan.

The study consisted of 84,928 IV injections of nonionic iodinated contrast media in adults. In this group, there were 545 (0.6%) patients who had allergic-like reactions, with 221 receiving treatment. The most commonly administered medications were diphenhydramine to 145 (27%) reacting patients, corticosteroids to 17 patients, albuterol to 16 patients, ephinephine to 15 patients, and nitroglycerin to eight patients. According to the study, 99% of the allergic-like reactions resolved completely within 24 hours. This included all 418 patients who had mild reactions, all 116 patients who had moderate reactions, and nine of the 11 patients who had severe reactions.

"Commonly used medications can be administered safely; however, treatment errors are not uncommon and in a few instances can lead to patient morbidity," said Dr. Cohan. "In our study, we found a number of instances in which non-recommended treatment was provided. These cases included the administration of oxygen by nasal cannula (rather than mask) and at lower than recommended doses, over-utilization of diphenhydramine (including to a few patients who were hypotensive), and the administration of higher than recommended doses of epinephrine, as well as occasional confusion about which concentrations of epinephrine should be injected in which manner (subcutaneously or intravenously). In our study, the most striking example of patient morbidity from non-recommended treatment occurred in the two patients who received doses of 1 mg of epinephrine in the absence of cardiopulmonary arrest, who both had cardiac complications. Fortunately, these complications were mild and transient and caused no serious morbidity," he said.

"We hope that after reading our study, radiologists, nurses, and technologists will agree that they must review the algorithms for treating contrast reactions on a regular basis (particularly issues related to diphenhydramine, oxygen, and epinephrine administration)," said Dr. Cohan. "In fact, we would suggest that such a review should probably occur at least twice a year. However, it is also consoling to know that even when patients have moderate or severe contrast reactions, the vast majority recover promptly and without any long term complications," he said.


'/>"/>

Contact: Necoya Tyson
necoya@arrs.org
703-858-4304
American Roentgen Ray Society
Source:Eurekalert

Related medicine news :

1. Allergic-like reactions occur in premedicated patients
2. London School of Hygiene to play key role in global collaboration on adverse drug reactions
3. DOCTORS OPPOSE MARYLAND VACCINE ROUNDUP: Expect Dangerous Reactions When Children Are Treated Like Cattle
4. MDs reactions to pharma marketing influenced by brand, side effects: Management Insights
5. Allergic reactions to gadolinium-based contrast agents are rare, study finds
6. U of I scientists aim to overcome allergic reactions to soy
7. PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements
8. Consumer Alert: Black Henna Tattoos Can Cause Serious Skin Reactions
9. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
10. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
11. DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRis Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
(Date:10/12/2017)... ... 12, 2017 , ... Farm Forward joins Bon ... leading institutions in announcing the launch of the Leadership Circle , a ... are raised for food. , Founding members of the Leadership Circle also include ...
(Date:10/12/2017)... Antonio, Texas (PRWEB) , ... October 12, 2017 ... ... device and biologics manufacturer, has expanded its executive staff with the addition of ... , In this role, Slott will develop the national distribution and sales network, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
Breaking Medicine Technology: